Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.

Parkinson's disease, caused by the loss of dopaminergic nigrostriatal projections, is a debilitating neurodegenerative disease characterized by bradykinesia, rigidity, tremor and postural instability. The dopamine precursor levodopa (L-dopa) is the most effective treatment for the amelioration of Parkinson's disease signs and symptoms, but long-term administration can lead to disabling motor fluctuations and L-dopa -induced dyskinesias (LIDs). Studies in rat striatal slices have shown dopamine to be an essential component of activity-dependent synaptic plasticity at the input to the basal ganglia, but dopamine is also released from ventrally projecting dendrites of the substantia nigra pars compacta (SNc) on the substantia nigra pars reticulata (SNr), a major output structure of the basal ganglia. We characterized synaptic plasticity in the SNr using field potentials evoked with a nearby microelectrode (fEPs), in 18 Parkinson's disease patients undergoing implantation of deep brain stimulating (DBS) electrodes in the subthalamic nucleus (STN). High frequency stimulation (HFS--four trains of 2 s at 100 Hz) in the SNr failed to induce a lasting change in test fEPs (1 Hz) amplitudes in patients OFF medication (decayed to baseline by 160 s). Following oral L-dopa administration, HFS induced a potentiation of the fEP amplitudes (+29.3% of baseline at 160 s following a plateau). Our findings suggest that extrastriatal dopamine modulates activity-dependent synaptic plasticity at basal ganglia output neurons. Dopamine medication state clearly impacts fEP amplitude, and the lasting nature of the increase is reminiscent of LTP-like changes, indicating that aberrant synaptic plasticity may play a role in the pathophysiology of Parkinson's disease.

[1]  J. Dostrovsky,et al.  Synchronized Neuronal Discharge in the Basal Ganglia of Parkinsonian Patients Is Limited to Oscillatory Activity , 2002, The Journal of Neuroscience.

[2]  H. Kita,et al.  Efferent projections of the subthalamic nucleus in the rat: Light and electron microscopic analysis with the PHA‐L method , 1987, The Journal of comparative neurology.

[3]  A. Lozano,et al.  Microelectrode Recordings in Movement Disorder Surgery , 2000 .

[4]  P. Calabresi,et al.  l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation , 2008, Neurobiology of Disease.

[5]  J. Aceves,et al.  Dopamine D1 receptor facilitation of depolarization‐induced release of γ‐amino‐butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q‐type calcium channels , 2007 .

[6]  G. Deuschl,et al.  Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[7]  J. Obeso,et al.  Pathophysiology of the basal ganglia in Parkinson's disease , 2000, Trends in Neurosciences.

[8]  J. Dostrovsky,et al.  Microstimulation-induced inhibition of neuronal firing in human globus pallidus. , 2000, Journal of neurophysiology.

[9]  R. J. Allan,et al.  Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease , 1998, Annals of neurology.

[10]  W. Precht,et al.  Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. , 1971, Brain research.

[11]  W. Precht,et al.  Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. , 1971, Brain research.

[12]  J. Bargas,et al.  Dopaminergic Modulation of Axon Collaterals Interconnecting Spiny Neurons of the Rat Striatum , 2003, The Journal of Neuroscience.

[13]  A. Parent,et al.  Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.

[14]  J. Dostrovsky,et al.  Effects of apomorphine on globus pallidus neurons in parkinsonian patients , 1997, Annals of neurology.

[15]  M. Pangalos,et al.  Activity-Dependent Ubiquitination of GABAA Receptors Regulates Their Accumulation at Synaptic Sites , 2007, The Journal of Neuroscience.

[16]  Mitsuo Yoshida,et al.  Monosynaptic inhibition of pallidal neurons by axon collaterals of caudato-nigral fibers , 2004, Experimental Brain Research.

[17]  J. Korf,et al.  Dopamine release in substantia nigra? , 1976, Nature.

[18]  J. Glowinski,et al.  Dendritic release of dopamine in the substantia nigra , 1981, Nature.

[19]  J. Yelnik.  Functional anatomy of the basal ganglia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[20]  C. Marsden,et al.  Cabergoline in the treatment of early parkinson's disease , 1997, Neurology.

[21]  Paul Greengard,et al.  Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia , 2003, Nature Neuroscience.

[22]  Y. Smith,et al.  Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat , 1989, Brain Research.

[23]  E. Moro,et al.  Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease , 1999, Neurology.

[24]  J. Mink,et al.  Deep brain stimulation. , 2006, Annual review of neuroscience.

[25]  G. Radnikow,et al.  Dopamine D1 Receptors Facilitate GABAASynaptic Currents in the Rat Substantia Nigra Pars Reticulata , 1998, The Journal of Neuroscience.

[26]  J. E. Vaughn,et al.  Immunocytochemical localization of GABAergic neurones at the electron microscopical level , 1981, The Histochemical Journal.

[27]  G. Damsma,et al.  Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  C. Altar,et al.  Topography of substantia nigra innervation by D1 receptor-containing striatal neurons , 1987, Brain Research.

[29]  M. Torricelli,et al.  Effects of Dexamethasone and Dexamethasone plus Naltrexone on Pituitary Response to GnRH and TRH in Normal Women , 1999, Hormone Research in Paediatrics.

[30]  J. Aceves,et al.  D-1 receptor mediated modulation of the release of γ-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  J. Bolam,et al.  Synaptic organisation of the basal ganglia , 2000, Journal of anatomy.

[32]  Francesca Morgante,et al.  Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. , 2006, Brain : a journal of neurology.

[33]  L. Hazrati,et al.  Functional anatomy of the basal ganglia , 1995 .

[34]  A. Benabid,et al.  Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 2003, The New England journal of medicine.

[35]  C. Warren Olanow,et al.  Levodopa motor complications in Parkinson's disease , 2000, Trends in Neurosciences.

[36]  F. Bergquist,et al.  Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission , 2006, The European journal of neuroscience.

[37]  J. E. Vaughn,et al.  The GABA Neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry , 1979, The Journal of comparative neurology.

[38]  T. Jessell,et al.  Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.

[39]  J. G. Nutt,et al.  Long-duration response to levodopa , 1995, Neurology.

[40]  T. Bliss,et al.  Plasticity in the human central nervous system. , 2006, Brain : a journal of neurology.

[41]  T. Mima,et al.  Altered plasticity of the human motor cortex in Parkinson's disease , 2006, Annals of neurology.

[42]  Rajesh Pahwa,et al.  Preoperative Clinical Predictors of Response to Bilateral Subthalamic Stimulation in Patients with Parkinson’s Disease , 2005, Stereotactic and Functional Neurosurgery.

[43]  J. Aceves,et al.  Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat , 1990, Neuroscience Letters.

[44]  Marc G Caron,et al.  Dopamine receptors and brain function , 1996, Neuropharmacology.

[45]  E. Abercrombie,et al.  Amphetamine‐induced release of dendritic dopamine in substantia nigra pars reticulata: D1‐mediated behavioral and electrophysiological effects , 1996, Synapse.

[46]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[47]  Matthew B. Stern,et al.  Bilateral Stimulation of the Subthalamic Nucleus in Parkinson’s Disease: Surgical Efficacy and Prediction of Outcome , 2004, Stereotactic and Functional Neurosurgery.

[48]  P. Brown.  Oscillatory nature of human basal ganglia activity: Relationship to the pathophysiology of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[49]  Paolo Calabresi,et al.  Dopamine-mediated regulation of corticostriatal synaptic plasticity , 2007, Trends in Neurosciences.

[50]  T. Chase,et al.  D-1 dopamine receptor changes after striatal quinolinic acid lesion. , 1987, European journal of pharmacology.

[51]  Y. Smith,et al.  Glutamate and GABA receptors and transporters in the basal ganglia: What does their subsynaptic localization reveal about their function? , 2006, Neuroscience.

[52]  S. Hernández,et al.  l-DOPA stimulates the release of [3H]γ-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats , 1991, Neuroscience Letters.